Prospective study for effectiveness of Etelcalcetide hydrochloride (Parsabiv) on patients treated with hemodialysis
Phase 4
- Conditions
- patients treated with hemodialysis
- Registration Number
- JPRN-UMIN000032637
- Lead Sponsor
- Zenjinkai Shinyokohama Daiichi Clinic Division of Nephrology
- Brief Summary
The study has discontinued.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients decided as incompetent for this study by the doctor Patietns showing contraindication for PARSABIV Patients showing low Ca(<8.4) before admonistration of PARSABIV Patients having malignant diseases Patients having serious diseases in liver, kidney (other than CRF), and heart. Patients treated with cinacalcet or bisphosphonate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of QOL (every month)
- Secondary Outcome Measures
Name Time Method Estimation od complication (every month) CTR/ECG (every month) bone mineral density and UCG(1 year later) General blood test (every month) Check of leftover medicine